[1]	Stolnicu S, Barsan I, Hoang L, et al, International Endocervical Adenocarcinoma Criteria and Classification (IECC):A new pathogenetic classification for invasive adenocarcinomas of the endocervix[J]. Am J Surg Pathol, 2018, 42(2):214-226. DOI:10.1097/PAS.0000000000000986. Cited in this article [4]

[2]	Nicolás I, Saco A, Barnadas E, et al. Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix[J]. Mod Pathol, 2020, 33(1):128-137. DOI:10.1038/s41379-019-0360-3. Cited in this article [1]

[3]	Poetsch M, Hemmerich M, Kakies C, et al. Alterations in the tumor suppressor genep16(INK4A) are associated with aggressive behavior of penile carcinomas[J]. Virchows Arch, 2011, 458(2):221-229. DOI:10.1007/s00428-010-1007-4. Cited in this article [1]

[4]	Yanagawa N, Osakabe M, Hayashi M, et al. Detection of HPV-DNA,p53 alterations and methylation in penile squamous cell carcinoma in Japanese men[J]. Pathol Int, 2008, 58(8):477-482. DOI:10.1111/j.1440-1827.2008.02259.x. Cited in this article [1]

[5]

Mills AM, Dirks DC, Poulter MD, et al. HR-HPV E6/E7 mRNA in situ hybridization:validation against PCR,DNA in situ hybridization,and p16 immunohistochemistry in 102 samples of cervical,vulvar,anal,and head and neck neoplasia[J]. Am J Surg Pathol, 2017, 41(5):607-615. DOI:10.1097/PAS.0000000000000800. Cited in this article [1]

[6]	da Mata S, Ferreira J, Nicolás I, et al. P16 and HPV genotype significance in HPV-associated cervical cancer-A large cohort of two tertiary referral centers[J]. Int J Mol Sci, 2021, 22(5):2294. DOI:10.3390/ijms22052294. Cited in this article [1]

[7]

Stolnicu S, Rakislova N, Morató A, et al. Cervical human papillomavirus-independent squamous cell carcinoma:A clinicopathological review and outcomes analysis compared with human papillomavirus-associated squamous cell carcinoma[J]. Mod Pathol, 2025, 38(6):100742. DOI:10.1016/j.modpat.2025.100742. Cited in this article [2]

[8]	Kulhan M, Bilgi A, Avci F, et al. Is HPV-negative cervical carcinoma a different type of cervical cancer?[J]. Eur Rev Med Pharmacol Sci, 2023, 27(19):9205-9212. DOI:10.26355/eurrev_202310_33948. Cited in this article [1]

[9]

Stolnicu S, Allison D, Patrichi A, et al. Invasive squamous cell carcinoma of the cervix:a review of morphological appearances encountered in human papillomavirus-associated and papillomavirus-independent tumors and precursor lesions[J]. Adv Anat Pathol, 2024, 31(1):1-14. DOI:10.1097/PAP.0000000000000411. Cited in this article [2]

[10]	Bhatla N, Aoki D, Sharma DN, et al. ancer of the cervix uteri:2025 update[J]. Int J Gynaecol Obstet, 2025, 171(Suppl 1):87-108. DOI:10.1002/ijgo.70277. Cited in this article [1]

[11]	Regauer S, Reich O, Kashofer K. HPV-negative squamous cell carcinomas of the cervix with special focus on intraepithelial precursor lesions[J]. Am J Surg Pathol, 2022, 46(2):147-158. DOI:10.1097/PAS.0000000000001778. Cited in this article [2]

[12]	Ikenberg H, Matthay K, Schmitt B, et al. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas[J]. Cancer, 1995, 76(1):57-66. DOI:10.1002/1097-0142(19950701)76:1<57::aid-cncr2820760108>3.0.co;2-4. Cited in this article [1]

[13]	Regauer S, Reich O. The histologic and molecular spectrum of highly differentiated hpv-independent cervical intraepithelial neoplasia[J]. Am J Surg Pathol, 2023, 47(8):942-949. DOI:10.1097/PAS.0000000000002067. Cited in this article [1]

[14]	Pors J, Tessier-Cloutier B, Thompson E, et al. Targeted molecular sequencing of recurrent and multifocal non-hpv-associated squamous cell carcinoma of the vulva[J]. Int J Gynecol Pathol, 2021, 40(4):391-399. Cited in this article [1]

[15]	Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer[J]. Nature, 2017, 543(7645):378-384. DOI:10.1038/nature21386. Cited in this article [1]

[16]	中国医师协会妇产科医师分会妇科肿瘤学组. 子宫颈胃型腺癌临床诊治中国专家共识(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(6):617-625. DOI:10.19538/j.fk2023060111. Cited in this article [2]

[17]	Pirog EC, Park KJ, Kiyokawa T, et al. Gastric-type adenocarcinoma of the cervix:tumor with wide range of histologic appearances[J]. Adv Anat Pathol, 2019, 26(1):1-12. DOI:10.1097/PAP.0000000000000216. Cited in this article [1]

[18]	Silverberg SG, Hurt WG. Minimal deviation adenocarcinoma("adenoma malignum")of the cervix:a reappraisal[J]. Am J Obstet Gynecol, 1975, 121(7):971-975. DOI:10.1016/0002-9378(75)90920-5. Cited in this article [1]

[19]	Stewart CJ, Frost F, Leake R, et al. Foamy gland changes in gastric-type endocervical neoplasia[J]. Pathology, 2015, 47(7):653-658. DOI:10.1097/PAT.0000000000000329. Cited in this article [1]

[20]	Talia KL, McCluggage WG. The developing spectrum of gastric-type cervical glandular lesions[J]. Pathology, 2018, 50(2):122-133. DOI:10.1016/j.pathol.2017.09.009. Cited in this article [1]

[21]	Kojima A, Mikami Y, Sudo T, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix[J]. Am J Surg Pathol, 2007, 31:664-672. DOI:10.1097/01.pas.0000213434.91868.b0. Cited in this article [1]

[22]	Yang J, Peng Y, Ding Y, et al. The clinicopathological and molecular characteristics of endocervical gastric-type adenocarcinoma and the use of claudin18.2 as a potential therapeutic target[J]. Mod Pathol, 2024, 37(10):100569. DOI:10.1016/j.modpat.2024.100569. Cited in this article [8]

[23]

Wada T, Ohishi Y, Kaku T, et al. Endocervical adenocarcinoma with morphologic features of both usual and gastric types:clinicopathologic and immunohistochemical analyses and high-risk HPV detection by in situ hybridization[J]. Am J Surg Pathol, 2017, 41(5):696-705. DOI:10.1097/PAS.0000000000000833. Cited in this article [2]

[24]	Wang S, Zhou X, Niu S, et al. Assessment of HER2 in gastric-type endocervical adenocarcinoma and its prognostic significance[J]. Mod Pathol, 2023, 36(6):100148. DOI:10.1016/j.modpat.2023.100148. Cited in this article [1]

[25]	Kyuno D, Takasawa A, Takasawa K, et al. Claudin-18.2 as a therapeutic target in cancers:cumulative findings from basic research and clinical trials[J]. Tissue Barriers, 2022, 10(1):1967080. DOI:10.1080/21688370.2021.1967080. Cited in this article [1]

[26]

Sahin U, Türeci Ö, Manikhas G, et al. FAST:a randomised phaseⅡstudy of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5):609-619. DOI:10.1016/j.annonc.2021.02.005. Cited in this article [1]

[27]	姜安绮, 康玉, 徐丛剑. Peutz-Jeghers综合征相关子宫颈胃型腺癌研究进展[J]. 中国实用妇科与产科杂志, 2023, 39(11):1144-1148.DOI:10.19538/j.fk2023110118. Cited in this article [1]

[28]	Peng WX, Kure S, Ishino K, et al. P16-positive continuous minimal deviation adenocarcinoma and gastric type adenocarcinoma in a patient with Peutz-Jegherssyndrome[J]. Int J Clin Exp Pathol, 2015, 8(5):5877-5882. Cited in this article [1]

[29]	Park E, Kim SW, Kim S, et al. Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix[J]. Mod Pathol, 2021, 34(3):637-646. DOI:10.1038/s41379-020-0614-0. Cited in this article [1]

[30]	朱滔. 子宫颈透明细胞癌诊治指南(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(8):810-818.DOI:10.19538/j.fk2024080110. Cited in this article [1]

[31]	Teixeira JC, Santos DZ, Campos CS, et al. Cervical cancer in women under 25 years of age and outside the screening age:Diagnosis profile and long-term outcomes[J]. Int J Gynaecol Obstet, 2021, 154(1):150-156. DOI:10.1002/ijgo.13553. Cited in this article [1]

[32]	Stolnicu S,KG, Guerra E, et al. Clear cell carcinoma (CCC) of the cervix is a human papillomavirus (HPV)-independent tumor associated with poor outcome:a comprehensive analysis of 58 cases[J]. Am J Surg Pathol, 2022, 46(6):765-773. DOI:10.1097/PAS.0000000000001863. Cited in this article [1]

[33]	倪新雨, 屈庆喜, 张师前. 原发性子宫颈透明细胞腺癌32例临床病理分析[J]. 中国实用妇科与产科杂志, 2024, 40(3):344-348.DOI:10.19538/j.fk2024030118. Cited in this article [1]

[34]

WHO Classification of Tumours Editorial Board. WHO Classification of Tumours,5th Edition,Volume 4:Female Genital Tumours[EB/OL].(2020-09-09)[2025-12-20]. https://www.iarc.who.int/news-events/publication-of-the-who-classification-of-tumours-5th-edition-volume-4-female-genital-tumours/. https://www.iarc.who.int/news-events/publication-of-the-who-classification-of-tumours-5th-edition-volume-4-female-genital-tumours/ Cited in this article [2]

[35]	Wijaya ST, Ngoi NY, Loh JW, et al. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC:a single center experience[J]. J Gynecol Oncol, 2024, 35(5):e69. DOI:10.3802/jgo.2024.35.e69. Cited in this article [1]

[36]	Ueno S, Sudo T, Oka N, et al. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma[J]. Int J Gynecol Cancer, 2013, 23(6):1084-1091.DOI:10.1097/IGC.0b013e3182981bdc. Cited in this article [1]

[37]

Boyd J, Takahashi H, Waggoner SE, et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero[J]. Cancer, 1996, 77(3):507-513. DOI:10.1002/(SICI)1097-0142(19960201)77:3<507::AID-CNCR12>3.0.CO;2-8. Cited in this article [1]

[38]	Nakamura K, Nakayama K, Minamoto T, et al. Lynch syndrome-related clear cell carcinoma of the cervix: a case report[J]. Int J Mol Sci, 2018, 19(4):979. DOI: 10.3390/ijms19040979. Cited in this article [1]

[39]	Huffman JW. Mesonephric remnants in the cervix[J]. Am J Obstet Gynecol, 1948, 56(1):23-40. DOI:10.1016/0002-9378(48)90188-4. Cited in this article [1]

[40]	Sneeden VD. Mesonephric lesions of the cervix;a practical means of demonstration and a suggestion of incidence[J]. Cancer, 1958, 11:334-336. DOI:10.1002/1097-0142(195803/04)11:2<334::aid-cncr2820110217>3.0.co;2-c. Cited in this article [1]

[41]	Pors J, Cheng A, Leo JM, et al. A comparison of GATA3,TTF1,CD10,and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract[J]. Am J Surg Pathol, 2018, 42(12):1596-1606. DOI:10.1097/PAS.0000000000001142. Cited in this article [1]

[42]	Mirkovic J, Sholl L, Garcia E, et al. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract[J]. Mod. Pathol, 2015, 28(11):1504-1514. DOI:10.1038/modpathol.2015.103. Cited in this article [1]